Association of humoral antitumor response with clinical benefit in catumaxomab-treated malignant ascites patients: Results from a phase IIIb study.

被引：0
|
作者：
Ruf, Peter
Suckstorff, Ivonne
Jaeger, Michael
Ernst, Christine
Seimetz, Diane
Lindhofer, Horst
机构：
[1] TRION Res GmbH, Martinsried, Germany
[2] Fresenius Biotech GmbH, Munich, Germany
[3] TRION Res GmbH, Munich, Germany
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2012年 / 30卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
2584
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Humoral response to catumaxomab correlates with clinical outcome: Results of the pivotal phase II/III study in patients with malignant ascites
    Ott, Marion G.
    Marme, Frederik
    Moldenhauer, Gerhard
    Lindhofer, Horst
    Hennig, Michael
    Spannagl, Rolf
    Essing, Mirko M.
    Linke, Rolf
    Seimetz, Diane
    INTERNATIONAL JOURNAL OF CANCER, 2012, 130 (09) : 2195 - 2203
  • [2] Catumaxomab with and without prednisolone in patients with malignant ascites due to epithelial cancer: Results from the phase IIIb CASIMAS study
    Sehouli, Jalid
    Wimberger, Pauline
    Vergote, Ignace B.
    Rosenberg, Per
    Schneeweiss, Andreas
    Bokemeyer, Carsten
    Salat, Christoph
    Scambia, Giovanni
    Berton-Rigaud, Dominique
    Siena, Salvatore
    Santoro, Armando
    Cervantes-Ruiperez, Andres
    Guastalla, Jean Paul
    Tournigand, Christophe
    Colombo, Nicoletta
    Dudnitchenko, Alexander Serg
    Bondar, Vladimir
    Westermann, A. M.
    Lordick, Florian
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [3] Catumaxomab: Pharmacodynamic and pharmacokinetic data from phase IIIb CASIMAS study in patients with malignant ascites.
    Rosenberg, Per
    Dudnitchenko, Alexander Serg
    Bondar, Vladimir
    Salat, Christoph
    Havsteen, Hanne
    Bokemeyer, Carsten
    Berton-Rigaud, Dominique
    Durando, Xavier
    Vergote, Ignace B.
    Wimberger, Pauline
    Lordick, Florian
    Lindhofer, Horst
    Martinius, Holger
    Sehouli, Jalid
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [4] Re-challenge with catumaxomab in patients with malignant ascites: results from the SECIMAS study
    Pietzner, Klaus
    Vergote, Ignace
    Santoro, Armando
    Chekerov, Radoslav
    Marme, Frederik
    Rosenberg, Per
    Martinius, Holger
    Friccius-Quecke, Hilke
    Sehouli, Jalid
    MEDICAL ONCOLOGY, 2014, 31 (12) : 1 - 8
  • [5] Catumaxomab with and without prednisolone premedication for the treatment of malignant ascites due to epithelial cancer: results of the randomised phase IIIb CASIMAS study
    Sehouli, Jalid
    Pietzner, Klaus
    Wimberger, Pauline
    Vergote, Ignace
    Rosenberg, Per
    Schneeweiss, Andreas
    Bokemeyer, Carsten
    Salat, Christoph
    Scambia, Giovanni
    Berton-Rigaud, Dominique
    Santoro, Armando
    Cervantes, Andres
    Tredan, Olivier
    Tournigand, Christophe
    Colombo, Nicoletta
    Dudnichenko, Alexander S.
    Westermann, Anneke
    Friccius-Quecke, Hilke
    Lordick, Florian
    MEDICAL ONCOLOGY, 2014, 31 (08)
  • [6] SECOND CYCLE OF CATUMAXOMAB TREATMENT IN PATIENTS WITH MALIGNANT ASCITES: RESULTS FROM THE SECIMAS STUDY
    Oskay-Oezcelik, G.
    Vergote, I. B.
    Santoro, A.
    Marme, F.
    Rosenberg, P.
    Sehouli, J.
    ANNALS OF ONCOLOGY, 2012, 23 : 172 - 173
  • [7] Re-challenge with catumaxomab in patients with malignant ascites: results from the SECIMAS study
    Klaus Pietzner
    Ignace Vergote
    Armando Santoro
    Radoslav Chekerov
    Frederik Marmé
    Per Rosenberg
    Holger Martinius
    Hilke Friccius-Quecke
    Jalid Sehouli
    Medical Oncology, 2014, 31
  • [8] Catumaxomab with and without prednisolone premedication for the treatment of malignant ascites due to epithelial cancer: results of the randomised phase IIIb CASIMAS study
    Jalid Sehouli
    Klaus Pietzner
    Pauline Wimberger
    Ignace Vergote
    Per Rosenberg
    Andreas Schneeweiss
    Carsten Bokemeyer
    Christoph Salat
    Giovanni Scambia
    Dominique Berton-Rigaud
    Armando Santoro
    Andrés Cervantes
    Olivier Trédan
    Christophe Tournigand
    Nicoletta Colombo
    Alexander S. Dudnichenko
    Anneke Westermann
    Hilke Friccius-Quecke
    Florian Lordick
    Medical Oncology, 2014, 31
  • [9] CATUMAXOMAB VERSUS CATUMAXOMAB PLUS PREDNISOLONE IN PATIENTS WITH MALIGNANT ASCITES DUE TO EPITHELIAL CANCER: RESULTS FROM THE CASIMAS STUDY
    Sehouli, J.
    Wimberger, P.
    Vergote, I. B.
    Rosenberg, P.
    Schneeweiss, A.
    Bokemeyer, C.
    Salat, C.
    Scambia, G.
    Berton-Rigaud, D.
    Lordick, F.
    ANNALS OF ONCOLOGY, 2012, 23 : 539 - 539
  • [10] Catumaxomab versus catumaxomab plus prednisolone in patients with malignant ascites due to epithelial cancer: results from the CASIMAS study
    Lordick, F.
    Wimberger, P.
    Vergote, I
    Rosenberg, P.
    Schneeweiss, A.
    Bokemeyer, C.
    Salat, C.
    Scambia, G.
    Berton-Rigaud, D.
    Siena, S.
    Santoro, A.
    Cervantes-Ruiperez, A.
    Guastalla, J. P.
    Tournigand, C.
    Colombo, N.
    Dudnitchenko, A. S.
    Bondar, V
    Westermann, A. M.
    Sehouli, J.
    ONKOLOGIE, 2012, 35 : 63 - 63
12345